Incidence of diabetes mellitus and neoplasia in Japanese short-statured children treated with growth hormone in the Genetics and Neuroendocrinology of Short Stature International Study (GeNeSIS)

Susumu Yokoya1, Tomonobu Hasegawa2, Keiichi Ozono3, Hiroyuki Tanaka4, Susumu Kanzaki5, Toshiaki Tanaka6, Kazuo Chihara7, Nan Jia8, Christopher J. Child9, Katsuichiro Ihara10, Jumpei Funai11, Noriyuki Iwamoto10, and Yoshiki Seino12

1Department of Medical Subspecialties, National Center for Child Health and Development, Tokyo, Japan
2Department of Pediatrics, School of Medicine, Keio University, Tokyo, Japan
3Department of Pediatrics, Graduate School of Medicine, Osaka University, Osaka, Japan
4Department of Pediatrics, Okayama Saiseikai General Hospital, Okayama, Japan
5Division of Pediatrics and Perinatology, Tottori University Faculty of Medicine, Tottori, Japan
6Tanaka Growth Clinic, Tokyo, Japan
7Hyogo Prefectural Kakogawa Medical Center, Kakogawa, Japan
8Lilly Research Laboratories, Eli Lilly and Company, Indiana, USA
9Lilly Research Laboratories, Eli Lilly and Company, Windlesham, UK
10Medical Science, Eli Lilly Japan K.K., Kobe, Japan
11Scientific Communications, Eli Lilly Japan K.K., Kobe, Japan
12JCHO Osaka Hospital, Osaka, Japan

Abstract. The primary goal of the Genetics and Neuroendocrinology of Short Stature International Study (GeNeSIS) was to assess the safety and effectiveness of Humatrope®, a GH preparation, in the treatment of pediatric patients with short stature. We report our findings in the GH-treated Japanese pediatric population focusing on the incidence of type 2 diabetes (T2D) and occurrence of neoplasms. A total of 2,345 Japanese patients were assessed for safety. During a mean observation period of 3.2 yr, T2D occurred in 3 patients (0.13%) and slowly progressive insulin-dependent diabetes mellitus (SPIDDM) related to underlying mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) in 1 patient (0.04%). Neoplasms were reported in 13 patients (0.56%), including 1 patient with brain tumor (germinoma) and 5 with craniopharyngiomas (4 recurrences); the remainder were benign, typically dermatological, neoplasms. The incidence of diabetes mellitus determined in the study did not differ from previous reports in GH-treated pediatric patients, and there was no apparent increase in the risk of new neoplastic lesions or malignant tumors.

Key words: diabetes mellitus, neoplasia, pediatric GH treatment, safety, short stature
Introduction

Recombinant human GH was initially approved in Japan in November 1988 for the treatment of children with significant GH deficiency (GHD) (1, 2). Humatrope® (somatropin [recombinant DNA (rDNA) origin]; Eli Lilly and Company [Indianapolis, IN, USA]) is a GH preparation marketed around the world; dosing varies across countries. Humatrope was launched in Japan in November 1989.

Treatment of short-statured children with recombinant human GH is associated with significant improvements in growth, leading to attainment of normal or near-normal final height (3, 4). Treatment with GH also has a beneficial impact on body composition (5), and GH is considered to be well tolerated, with few reported adverse reactions (3, 4, 6, 7).

In addition to its growth promotion effects, GH is responsible for critical parts of the metabolism of glucose, lipids, and proteins in humans. It reduces oxidation of glucose and uptake of glucose in the muscles and fosters gluconeogenesis (8, 9); it also accelerates lipolysis, lipid oxidation, and protein synthesis; lessens breakdown of proteins and amino acids; and reduces formation of hepatic urea.

Based on the physiologic actions of endogenous GH (and exogenous somatropin) as an insulin antagonist, it has been suggested that treatment with somatropin may cause alterations in glucose metabolism, and children with some growth disorders may already be at risk for impaired glucose metabolism. New-onset cases of diabetes have been reported in some GH-treated children, and the risks are of clinical interest (10–12).

The possibility of increased risk of cancer in patients receiving GH treatment has been discussed since the first report of leukemia in a GH-deficient child undergoing GH replacement therapy shortly after its approval in the United States (2, 10, 13). The role of the GH-IGF-I axis in tumorigenesis has been studied extensively; although it is known that IGF-I is a mitogen, animal models suggest permissive rather than causative roles for both IGF-I and GH in tumorigenesis (2, 14).

Because there are few reports on the incidence of diabetes or neoplastic disease in GH-treated children who have received the relatively lower dose of GH used in Japan, we analyzed the incidence of both of these conditions among Japanese short-statured children treated with GH and followed in the observational Genetics and Neuroendocrinology of Short Stature International Study (GeNeSIS).

Subjects and Methods

Study design and overall study population

GeNeSIS was an open-label, multinational observational study (ClinicalTrials.gov, NCT01088412). It began in 1999 and ran through 2015, enrolling 22,845 patients in 30 countries around the world, including Japan. The goal of GeNeSIS was to assess the safety and effectiveness of Humatrope in the treatment of pediatric patients with short stature. Primary safety objectives of the study included examining the important potential risk of diabetes in subgroups of somatropin-treated children and the occurrence of new cases of neoplasias in children treated with somatropin. The study collected information on the clinical management and treatment outcomes of pediatric patients with growth disorders who were treated with the recombinant human GH somatropin.

The study met international guidelines for postmarketing surveillance studies (15) and was conducted in accordance with the Declaration of Helsinki. The protocol was approved at each study site by an Institutional Review Board, and written informed consent was provided for pediatric patients by parents or guardians according to national regulations.

We assessed the safety of GH treatment in Japanese pediatric patients enrolled in GeNeSIS, in particular to determine the incidence of type 2
diabetes (T2D) and the occurrence of treatment-emergent neoplasms during GH replacement therapy. Inclusion criteria and other background information for this population have been previously reported (16). An interim report, which included approximately one-half of the enrolled Japanese patients, was published in 2013 (17). In that paper, the mean GH doses ranged from 0.19 mg/kg/week for patients with GHD to 0.33 mg/kg/week for patients with Turner syndrome.

Analysis methods

Adverse events occurring in temporal association with somatropin treatment were collected on case report forms by study site personnel. Serious adverse events (SAEs) were defined as in the International Conference on Harmonisation guidelines (E2A 1994).

Patients were included in safety analyses as long as date of birth and treatment status (treated or untreated) were available. For patients to be included in analyses of diabetes or primary cancer, the following data were required to be available: gender, dates of first and last visits, and information on history of neoplasia or diabetes (yes or no), respectively.

Results

Patients and disposition

A total of 2,345 GH-treated Japanese patients enrolled between 2000 and 2013 who met the safety evaluable criteria were included in the analyses. The majority of these patients (n = 2,106 [89.8%]) had been diagnosed with GHD; the only other growth-related condition affecting 5% or more of enrolled patients was Turner syndrome (n = 125 [5.3%]). A total of 57 patients had been diagnosed with GHD resulting from an intracranial tumor; 25 of these patients had a preexisting craniopharyngioma.

Key demographic characteristics for the 2,234 GH-treated Japanese patients who met criteria for safety analyses (described above) and had a baseline height measurement available are presented in Table 1. More than half of the patients (59.4%) were male. Mean (SD) age at the start of GH treatment was 8.94 (3.50) yr, and mean (SD) bone age SD score (SDS) (Greulich-Pyle [GP] method) was −2.46 (1.35). Mean (SD) height SDS was −2.66 (0.68). Mean (SD) weight was 22.39 (9.39) kg; mean (SD) weight SDS and body mass index (BMI) SDS were −1.49 (2.52) and −0.06 (0.96), respectively. The mean (SD) GH dose for GHD during the study was 0.19 (0.03) mg/kg/wk. Mean and median follow-up periods in the study for these patients were 3.2 yr and 2.7 yr, respectively.

Table 2 presents reasons for discontinuation of the patients during the study by baseline GHD condition and overall. Due to the nature of Japanese regulatory assessments of observational studies, GeNeSIS Japan was conducted in 2 separate segments, requiring the discontinuation of several patients by the sponsor at the end of the first segment, and sponsor decision was the most frequent reason for patient discontinuation overall (n = 1,458 [64.6%]). The only other reason for discontinuation of 10% or more of patients overall was patients who attained final height according to the investigator (n = 236 [10.5%]). Patient disposition for all patients is presented in Fig. 1.

General safety

Treatment-emergent adverse events (TEAEs), including relatedness to GH therapy as assessed by the investigators, are summarized in Table 3 for patients who had at least 1 follow-up visit. Approximately 16% of patients overall experienced at least 1 TEAE. The only TEAEs occurring in 1% or more of patients were hypothyroidism (n = 55 [2.4%]) and precocious puberty (n = 34 [1.5%]). Diagnoses of precocious puberty were as recorded by the investigators according to Tanner stages (18, 19).

SAEs occurring in more than 1 patient, including relatedness to GH therapy as assessed by the investigators, are summarized in Table 4.
The only SAEs occurring in more than 1 patient overall were craniopharyngioma (n = 4 [0.17%]; pneumonia (n = 3 [0.13%]); and inguinal hernia, gastroenteritis, and influenza (n = 2 [0.09%], each).

### Diabetes

New-onset T2D occurred in 3 patients (0.13%), and slowly progressive insulin-independent diabetes mellitus (SPIIDDM) related to the underlying syndrome of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) occurred in 1 patient (0.04%; Table 5). Risk factors were identified for all 3 of the patients with new-onset T2D: a patient with Turner syndrome with preexisting impaired glucose tolerance also reported, a patient with a small for gestational age (SGA) diagnosis (Russell-Silver syndrome), and a patient with organic GHD following total body irradiation for acute lymphocytic leukemia. The patient with Russell-Silver syndrome

| Variable | All | GHD | TS | ISS | SHOX-D | SGA | Other | UNK |
|----------|-----|-----|----|-----|--------|-----|-------|-----|
| Male, n (%) | 1,326 | 1,263 | 1 * | 1 | 0 | 17 | 32 | 12 |
| CA (y) | 8.94 | 9.01 | 8.23 | 12.36 | 4.65 | 7.63 | 8.13 | 9.81 |
| BAGP (SDS) | −2.46 | −2.51 | −1.84 | −1.21 | − | −1.79 | −2.66 | −2.06 |
| Ht (SDS) | −2.66 | −2.64 | −2.84 | −2.41 | −2.56 | −2.76 | −3.11 | −2.57 |
| Weight (kg) | 22.39 | 22.47 | 22.53 | 29.84 | 14.00 | 18.39 | 20.54 | 23.28 |
| Weight (SDS) | −1.49 | −1.50 | −1.18 | −1.60 | −1.05 | −1.62 | −1.57 | −1.57 |
| BMI (SDS) | −0.06 | −0.09 | 0.45 | −0.45 | 0.50 | −0.17 | 0.16 | −0.50 |
| IGF-I (SDS) | −1.35 | −1.41 | −0.88 | −2.25 | −0.66 | −0.77 | −1.14 | −0.65 |
| GH dose (mg/kg/wk) | | | | | | | | |
| Mean (SD) | 0.20 | 0.19 | 0.33 | 0.18 | 0.20 | 0.19 | 0.19 | 0.19 |
| Median | 0.18 | 0.18 | 0.35 | 0.35 | 0.17 | 0.20 | 0.18 | 0.18 |
| Min, Max | 0.02, 0.86 | 0.02, 0.86 | 0.04, 0.20 | 0.15, 0.20 | 0.20, 0.20 | 0.03, 0.29 | 0.09, 0.30 | 0.16, 0.26 |

Data are mean (SD) unless otherwise indicated. BAGP, bone age (Greulich-Pyle method); BMI, body mass index; CA, chronological age at diagnosis; GHD, GH deficiency; Ht, height; ISS, idiopathic short stature; Max, maximum; Min, minimum; NA, not applicable; SD, standard deviation; SDS, standard deviation score; SGA, short children born small for gestational age; SHOX-D, short stature homeobox-containing gene deficiency; TH, target height; TS, Turner syndrome; UNK, unknown. * Male gender was indicated for 1 patient with reported diagnosis of Turner syndrome. It is unclear whether the entry was in error or represented a case of male Turner syndrome (ie, Noonan syndrome).
was diagnosed with T2D 2.9 yr after starting treatment with GH. The patient discontinued GH treatment and was hospitalized for 2 wk. The blood glucose level was rapidly improved and normalized by diet therapy without diabetes medication. A second patient was diagnosed with T2D after GH treatment for 2.6 yr. He received total body irradiation and chemotherapy due to acute lymphocytic leukemia. His fasting blood glucose level was 259 mg/dL and HbA1c value was 6.7% at the diagnosis of diabetes. After he discontinued GH treatment, his blood glucose level was normalized by diet therapy.

### Table 2  Reasons for study discontinuation for GH-treated patients by diagnostic group at baseline (safety evaluable population)

| Reason                                | All   | GHD   | TS    | ISS   | SHOX-D | SGA | Other | UNK  |
|---------------------------------------|-------|-------|-------|-------|--------|-----|-------|------|
|                                       | N = 2,345 | N = 2,106 | N = 125 | N = 5 | N = 1 | N = 29 | N = 61 | N = 18 |
| Unable to contact patient (lost to follow-up) | 99 (4.4) | 96 (4.7) | 1 (0.8) | 0 | 0 | 2 | 0 |
| Patient moved | 59 (2.6) | 50 (2.5) | 6 (5.0) | 0 | 0 | 1 | 0 |
| Sponsor decision (study or patient discontinued by sponsor) | 1,458 (64.6) | 1,316 (64.5) | 83 (69.7) | 3 (60.0) | 19 (100.0) | 34 (65.5) | 2 (56.7) | 2 (40.0) |
| Patient/parent decision | 158 (7.0) | 149 (7.3) | 4 (3.4) | 0 | 0 | 3 | 2 |
| Physician decision | 109 (4.8) | 97 (4.8) | 7 (5.9) | 1 (20.0) | 0 | 2 | 1 |
| Adverse event | 8 (0.4) | 7 (0.3) | 0 | 0 | 0 | 0 | 1 | 0 |
| Final height attained | 236 (10.5) | 216 (10.6) | 7 (5.9) | 1 (20.0) | 0 | 3 | 7 | 2 |
| Patient transferred to HypoCCS study | 1 (0.0) | 1 (0.0) | 0 | 0 | 0 | 0 | 0 | 0 |
| Third party required patient to change brand of GH | 10 (0.4) | 8 (0.4) | 1 (0.8) | 0 | 0 | 0 | 1 | 0 |
| Other | 120 (5.3) | 99 (4.9) | 10 (8.4) | 0 | 0 | 0 | 11 | 0 |
| Study summary completed | 2,258 (8.0) | 2,039 (8.0) | 119 (8.4) | 5 | 1 | 29 | 60 | 5 |

Data are number (%) of patients. GHD, GH deficiency; HypoCCS, Hypopituitary Control and Complications Study; ISS, idiopathic short stature; SGA, short children born small for gestational age; SHOX-D, short stature homeobox-containing gene deficiency; TS, Turner syndrome; UNK, unknown.

### Neoplasms

Treatment-emergent neoplasms were reported for 13 patients (0.56%), including 5 patients with craniopharygiomas and 1 patient with brain neoplasm. The brain neoplasm, identified as *de novo* germinoma, was the only treatment-emergent malignancy observed. Besides the craniopharygiomas and the brain neoplasm, the other 6 patients with treatment-emergent neoplasms had benign neoplasms: melanocytic naevus in 2 patients and benign hair follicle tumour, lipoma, neurofibroma, and benign tongue neoplasm in 1 patient each. Among the 5 patients with craniopharygioma, 4 were recurrences. Three
of the cases were considered causally unrelated to GH treatment; the causal relationship was undetermined for 2 of the cases. The patient with de novo germinoma had a preexisting diagnosis of hypophysitis but was subsequently diagnosed with germinoma approximately 1 month after starting GH therapy. Table 6 provides key information for the 7 patients considered to have noteworthy neoplasms: in addition to the 6 cases discussed above, this includes a case of recurrent medulloblastoma that was reported as a TEAE but was found to have existed prior to initiation of therapy; causal relation with GH treatment was ruled out.

**Discussion**

Among Japanese patients treated in GeNeSIS, new-onset T2D was diagnosed in 3 patients (0.13%). Preexisting craniopharyngioma was found in 25 of the 57 patients with organic GHD due to intracranial tumors and recurred in 4 of these patients (16%). Data from the Pfizer International Growth Study (KIGS) have indicated an incidence rate of 0.36% for diabetes mellitus during a median GH treatment period of 2.9 years (11) and a recurrence-free survival rate of 63% for craniopharyngioma patients during a mean GH treatment period of 10.3 yr (20), neither of which was significantly different from our results.

Data from global GeNeSIS demonstrated that GH treatment did not affect the incidence of type 1 diabetes; however, the incidence of T2D in KIGS was 34.4 cases per 100,000 patient-years of GH treatment (11), and in a previous analysis of global GeNeSIS it was reported to be six-fold higher than the rate reported in the general population, stratified for age and ethnicity (12). In the latter analysis, among the 11 patients with new-onset T2D during the study, risk factors for diabetes were identified in 10 patients (12). In Japanese patients, risk factors were identified for all 3 of the patients...
Table 3  Summary of TEAEs and specific medical conditions for GH-treated patients (safety population with at least 1 follow-up visit available)

| TEAE or Specific Medical Condition | Common TEAEs | GH relatedness | GH relatedness |
|-----------------------------------|--------------|----------------|---------------|
| All (N = 2,308)                   | Patients with at least 1 TEAE | Yes | No | UNK |
| Hypothyroidism                    | 55 (2.38) | 6 (0.26) | 41 (1.78) | 8 (0.35) |
| Precocious puberty                | 34 (1.47) | 0 | 33 (1.43) | 1 (0.04) |
| Upper respiratory tract inflammation | 19 (0.82) | 0 | 19 (0.82) | 0 |
| Asthma                            | 17 (0.74) | 0 | 17 (0.74) | 0 |
| Arthralgia                        | 16 (0.69) | 12 (0.52) | 4 (0.17) | 0 |
| Bronchitis                        | 13 (0.56) | 0 | 12 (0.52) | 1 (0.04) |
| Influenza                         | 13 (0.56) | 0 | 13 (0.56) | 0 |
| Hypogonadism                      | 11 (0.48) | 0 | 11 (0.48) | 0 |
| Pharyngitis                       | 11 (0.48) | 0 | 11 (0.48) | 0 |
| Rhinitis allergic                 | 11 (0.48) | 0 | 10 (0.43) | 1 (0.04) |
| Secondary hypothyroidism          | 10 (0.43) | 0 | 10 (0.43) | 0 |
| Scoliosis                         | 10 (0.43) | 4 (0.17) | 6 (0.26) | 0 |

Specific medical conditions related to neoplasia and diabetes

| Condition                        | GH relatedness |
|----------------------------------|----------------|
| Craniopharyngioma                | Yes | No | Unknown |
| Type 2 diabetes mellitus         | 5 (0.22) | 1 | 4 | 0 |
| Diabetes mellitus ^               | 2 (0.09) | 0 | 1 | 1 |
| Melanocytic naevus ^              | 2 (0.09) | 0 | 1 | 1 |
| Medulloblastoma ^                 | 1 (0.04) | 0 | 1 | 0 |
| Tongue neoplasm benign           | 1 (0.04) | 0 | 1 | 0 |
| Neurofibroma                      | 1 (0.04) | 1 | 0 | 0 |
| Lipoma                            | 1 (0.04) | 0 | 1 | 0 |
| Hair follicle tumour benign       | 1 (0.04) | 0 | 1 | 0 |
| Brain neoplasm ^                  | 1 (0.04) | 0 | 1 | 0 |

Data are number of patients (%). Data are for patients with a Visit 1 and at least 1 follow-up visit available. GH relatedness assigned by investigators. Events coded using MedDRA version 18.1. MedDRA, Medical Dictionary for Regulatory Activities; TEAE, treatment-emergent adverse event; UNK, unknown. ^ Includes type 2 diabetes and slowly progressive insulin dependent diabetes mellitus (SPIDDM). ^ Recurrence (not TEAE). ^ Germinoma.

Table 4  SAEs occurring in 2 or more patients (safety evaluable population)

| SAE                              | GH relatedness |
|----------------------------------|----------------|
| All (N = 2,345)                  | Yes | No | Unknown |
| Patients with at least 1 SAE     | 32 (1.36) | 6 | 25 | 1 |
| Craniopharyngioma                | 4 (0.17) | 1 | 3 | 0 |
| Pneumonia                        | 3 (0.13) | 0 | 3 | 0 |
| Gastroenteritis                  | 2 (0.09) | 0 | 2 | 0 |
| Influenza                        | 2 (0.09) | 0 | 2 | 0 |
| Inguinal hernia                  | 2 (0.09) | 0 | 2 | 0 |

Data are number of patients (%). Events coded using MedDRA version 18.1. GH relatedness assigned by investigators. MedDRA, Medical Dictionary for Regulatory Activities; SAE, serious adverse event.
### Table 5. Listing of new-onset diabetes cases and relevant patient histories for GH-treated patients (safety evaluable population)

| Type of DM | Diagnosis                          | DM onset age (yr) | Time to DM from start of GH therapy (yr) | Puberty at start of GH therapy | Additional risk factors | BMI (SDS) at Visit 1 | GH dose (mg/kg/wk) | GH status          |
|------------|------------------------------------|-------------------|------------------------------------------|--------------------------------|------------------------|---------------------|---------------------|-------------------|
| Type 2     | Turner syndrome                    | 17.4              | 5.0                                      | No                             | IGT                   | 1.15                | 0.34                | Discontinued       |
| Type 2     | SGA (Russell-Silver syndrome)      | 10.1              | 2.9                                      | No                             | NR                    | −0.74               | 0.29                | Discontinued       |
| Type 2     | Idiopathic GHD                     | 15.3              | 2.6                                      | No                             | Total body irradiation| −0.42               | 0.18                | Discontinued       |
| SPIDDM     | Organic GHD (mitochondrial disease)| 16.8              | 3.0                                      | No                             | FH (+) Mother: DM     | 0.98                | 0.19                | Discontinued       |

BMI, body mass index; DM, diabetes mellitus; FH, family history; GHD, GH deficiency; IGT, impaired glucose tolerance; NR, none recorded; SDS, standard deviation score; SGA, small for gestational age; SPIDDM, slowly progressive insulin-dependent diabetes mellitus.

### Table 6. Summary of key cases of neoplasia

#### Recurrent events

| Type of neoplasm diagnosed | Sex | Age at enrollment (yr) | Age at first diagnosis of neoplasm (yr) | Age at start of GH treatment (yr) | Age at detection of recurrence (yr) | Duration of GH treatment before recurrence (yr) | GH status a | Investigator-assessed causal relationship to GH |
|----------------------------|-----|------------------------|----------------------------------------|-----------------------------------|-------------------------------------|-----------------------------------------------|-------------|-----------------------------------------------|
| Craniopharyngioma          | F   | 8                      | 9                                      | 8                                 | 10                                  | 1.6                                           | Restarted   | Unknown                                       |
| Craniopharyngioma          | F   | 11                     | 7                                      | 11                                | 13                                  | 2.8                                           | Discontinued | Unknown                                       |
| Craniopharyngioma          | M   | 8                      | 8                                      | 8                                 | 10                                  | 2                                             | Continued   | No                                            |
| Craniopharyngioma          | M   | 7                      | 5                                      | 7                                 | 9                                   | 2 yr                                          | Restarted   | No                                            |
| Medulloblastoma            | F   | 9                      | 3                                      | 9                                 | 9                                   | Preexisting                                   | Continued   | No                                            |

| Type of neoplasm diagnosed | Sex | Age at enrollment (yr) | Age at start of GH treatment (yr) | Age at detection of neoplasm (yr) | Duration of GH treatment before detection of neoplasm | GH status a | Investigator-assessed causal relationship to GH |
|----------------------------|-----|------------------------|-----------------------------------|-----------------------------------|---------------------------------------------|-------------|-----------------------------------------------|
| Craniopharyngioma          | M   | 10                     | 10                                | 10                                | 43 days                                     | Discontinued | No                                            |
| Germinoma (brain neoplasm) | F   | 8                      | 8                                 | 7 (suspected)                     | 1 month                                    | Discontinued | No                                            |

F, female; GHD, GH deficiency; M, male; N/A, not available. a Status immediately following recurrence or detection.
with new-onset T2D: a patient with Turner syndrome with preexisting impaired glucose tolerance also reported, a patient with a small for gestational age (SGA) diagnosis (Russell-Silver syndrome), and a patient with organic GHD following total body irradiation for acute lymphocytic leukemia. A study of patients with Turner syndrome suggested that GH impairs beta-cell function and predisposes patients to diabetes (21). A hyperinsulinemic clamp study in children born SGA showed reduced insulin sensitivity, which may contribute to an increased risk of diabetes later in life (22). In a retrospective study that compared childhood cancer survivors with their siblings, the survivors treated with total-body or abdominal irradiation had an increased risk of diabetes in later life that appeared to be unrelated to their BMI or physical activity levels (23). Additionally, there was a case of SPIDDM in the patient with underlying MELAS; mitochondrial dysfunction might play an important role in diabetes pathophysiology due to the consequences of decreased energy production (ATP), and mitochondrial diseases have been associated with diabetes (24).

The possibility that patients receiving GH are at increased risk of cancer (de novo cases as well as recurrence of previously treated tumors) has been discussed for many years (13, 25). However, based on the KIGS data, there was no evidence that GH treatment in growth-disordered pediatric patients resulted in an increased risk compared with the general population (26), and children without a history of malignancy treated with GH in global GeNeSIS did not have a higher risk of cancer during treatment when compared with general-population cancer registries (2). Following the early report of cases of leukemia in GH-treated pediatric patients (13), multiple studies have found the rates of leukemia in GH-treated patients without leukemia risk factors to be similar to those of the general population (27–29). There was only a single case of potential new-onset primary cancer reported in Japanese patients: the case of pituitary germinoma, which was identified 5 wk after initiation of somatropin therapy. Previous magnetic resonance imaging (MRI) in this patient had identified hypophysitis, and cases of hypophysitis preceding or masking a diagnosis of germinoma have previously been described (30). This fact, coupled with the short time between the start of GH treatment and diagnosis of the tumor, suggests that the germinoma may have been present before initiation of GH therapy, but misdiagnosed as hypophysitis. Generally, germinoma has been identified in the pineal or the hypothalamic-pituitary region in which teratoma, astrocytoma, and hypophysitis, including Langerhans cell histiocytosis and sarcoidosis, has been diagnosed. A manuscript on neuroimaging suggests that the common pineal region tumors have no pathognomonic imaging patterns (31). Additionally, some biopsies are either nondiagnostic or misdiagnosed due to the complexity of the masses and their high vascularity, leading to insufficient tissue (32), which indicates that one imaging study would be insufficient for definitive diagnosis. Mootha et al. suggested that a contrast-enhanced brain MRI and serial follow-up scan in a short term was useful for detecting subtle abnormalities in the hypothalamic-pituitary region (33).

In a recently published analysis of the global GeNeSIS database, the standardized incidence ratio (95% confidence interval [CI]) for primary cancer in GH-treated children compared with a country-, age-, and sex-matched cohort of the general population was 1.02 (0.54–1.75), and the crude incidence (95% CI) was 20.1 (10.7–34.3) cases per 100,000 person-years (2). These findings were based on 13 observed primary cancer cases, including the case of germinoma from Japan. Reports from the Childhood Cancer Survivor Study (CCSS) indicated that GH treatment was associated with an increased relative risk of second neoplasms (SN) (34, 35): the rate ratio of GH-treated survivors developing an SN compared with non-GH-treated survivors was 2.15 (95% CI 1.3–3.5; p < 0.002) (34). However,
A more recent analysis specifically for SN of the central nervous system (CNS) showed that the overall risk of occurrence of a CNS SN was not statistically significantly increased with GH exposure (36). In Japanese GeNeSIS patients, no cases of SN were reported. Of the 57 GH-treated patients in the study with any type of intracranial tumor, 25 patients had craniopharyngioma; 4 of these 25 (16%) had a recurrence of the tumor while participating in GeNeSIS. It has been reported that craniopharyngiomas account for approximately 5–10% of intracranial tumors in pediatric patients (37). A recent meta-analysis of 15 studies indicated that the recurrence or progression of intracranial tumors was not associated with GH therapy for any age group (relative risk [RR] 0.48; 95% CI 0.39–0.56) (38). Similarly, for children, the pooled RR (95% CI) was 0.44 (0.34–0.50), indicating that GH therapy did not increase the risk of recurrence or progression of intracranial tumors, craniopharyngioma, medulloblastoma, astrocytoma, or glioma (38).

Rates of recurrence of craniopharyngiomas (including those that were excised, and across pediatric and adult studies) have been reported to range from 5−57% (39); the frequency of recurrence in the KIGS data was 11.7% (20).

Our study has a number of limitations to consider. First, because it was an observational study, it has limited value for assessing causality. There was no comparator treatment group, and without sponsor monitoring of patient medical records, the reporting of incident cases was dependent on the investigative sites. Although the sites were reminded of the importance of adverse event reporting throughout the study, potential underreporting of event cases must be considered because multiple data modules from the GeNeSIS and corporate pharmacovigilance databases were used to ascertain cases. Second, although the overall duration of GeNeSIS was approximately 15 yr, the average follow-up time per patient in Japan GeNeSIS was relatively short (a mean of 3.2 yr for GH-treated patients) because data from patients previously treated with GH before entering the study were excluded from the analyses. This comparatively short duration might not have been sufficient to assess incident rates by calculating events per patient-year. However, the large number of patients enrolled allowed detection of adverse events occurring even infrequently, and the observational study design allowed evaluation of typical GH treatment in real-world Japanese clinical practice.

In conclusion, new-onset cases of T2D were reported in Japanese patients followed in GeNeSIS, but all had risk factors for development of abnormal glucose metabolism, and our findings did not differ from previous reports of diabetes in GH-treated pediatric patients with short stature. There was no apparent increase in the risk of new neoplastic lesions or malignant tumors in Japanese patients followed in GeNeSIS.

Conflict of Interest: NJ and CJC are employees of Eli Lilly and Company. KI, JF, and NI are employees of Eli Lilly Japan K.K. Other authors have no conflict of interest to disclose.

Funding Source: This analysis was funded by Eli Lilly K.K. (Kobe, Japan).

Acknowledgments

The authors thank Mary Re of inVentiv Health Clinical (Ann Arbor, MI, USA) for assistance with writing.

References

1. Tanaka T. Growth hormone treatment in Japan: past, present, and future. Pediatr Endocrinol Rev 2012;10 (Suppl 1): 89–97. [Medline]
2. Child CJ, Zimmermann AG, Jia N, Robison LL, Brämswig JH, Blum WF. Assessment of primary cancer incidence in growth hormone-treated children: comparison of a multinational prospective observational study with population databases. Horm Res Paediatr 2016;85: 198–206.
3. Cappa M, Iughetti L, Loche S, Maghnie M, Votto A, GeNeSIS National Board on behalf of the GeNeSIS Italian Investigators. Efficacy and safety of growth hormone treatment in children with short stature: the Italian cohort of the GeNeSIS clinical study. J Endocrinol Invest 2016;39: 667–77. [Medline] [CrossRef]

4. Luzuriaga Tomás C, Oyarzabal Irigoyen M, Caveda Cepas E, Vázquez Salvi LA, García-Pérez LE, el grupo de investigadores españoles del estudio GeNeSIS. Safety and efficacy of growth hormone treatment: GeNeSIS study in Spain. An Pediatr (Barc) 2016;84: 139–47 (in Spanish). [Medline]

5. Nørrelund H, Vahl N, Juul A, Møller N, Alberti KG, Skakkebaek NE, et al. Continuation of growth hormone (GH) therapy in GH-deficient patients during transition from childhood to adulthood: impact on insulin sensitivity and substrate metabolism. J Clin Endocrinol Metab 2000;85: 1912–7. [Medline] [CrossRef]

6. Allen DB, Backeljauw P, Bidlingmaier M, Biller BM, Boguszewski M, Burman P, et al. GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults. Eur J Endocrinol 2016;174: 1–9. [Medline] [CrossRef]

7. Sävendahl L, Pournara E, Pedersen BT, Blankenstein O. Is safety of childhood growth hormone therapy related to dose? Data from a large observational study. Eur J Endocrinol 2016;174: 681–91. [Medline] [CrossRef]

8. Luger A, Mattsson AF, Koltowska-Häggström M, Thunander M, Göth M, Verhelst J, et al. Incidence of diabetes mellitus and evolution of glucose parameters in growth hormone-deficient subjects during growth hormone replacement therapy: a long-term observational study. Diabetes Care 2012;35: 57–62. [Medline] [CrossRef]

9. Møller N, Jørgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev 2009;30: 152–77. [Medline] [CrossRef]

10. Clayton PE, Cowell CT. Safety issues in children and adolescents during growth hormone therapy: a review. Growth Horm IGF Res 2000;10: 306–17. [Medline] [CrossRef]

11. Cutfield WS, Wilton P, Bennmarker H, Albertsson-Wikland K, Chatelain P, Ranke MB, et al. Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment. Lancet 2000;355: 610–3. [Medline] [CrossRef]

12. Child CJ, Zimmermann AG, Scott RS, Cutler GB Jr, Battelino T, Blum WF, GeNeSIS International Advisory Board. Prevalence and incidence of diabetes mellitus in GH-treated children and adolescents: analysis from the GeNeSIS observational research program. J Clin Endocrinol Metab 2011;96: E1025–34. [Medline] [CrossRef]

13. Watanabe S, Mizuno S, Oshima LH, Tsunematsu Y, Fujimoto J, Komiyama A. Leukemia and other malignancies among GH users. J Pediatr Endocrinol Metab 1993;6: 99–108. [Medline] [CrossRef]

14. Renehan AG, Zwahlen M, Minder C, O’Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004;363: 1346–53. [Medline] [CrossRef]

15. Herbold M. International guidelines on post-authorisation research and surveillance. European Economic Community. Pharmacopsychiatry 1997;30(Suppl): 62–4. [Medline] [CrossRef]

16. Tanaka T, Hasegawa T, Ozono K, Tanaka H, Kanzaki S, Yokoya S, et al. Effect of growth hormone treatment on quality of life in Japanese children with growth hormone deficiency: an analysis from a prospective observational study. Clin Pediatr Endocrinol 2014;23: 83–92. [Medline] [CrossRef]

17. Tai S, Tanaka T, Hasegawa T, Ozono K, Tanaka H, Kanzaki S, et al. An observational study of the effectiveness and safety of growth hormone (Humatrope®) treatment in Japanese children with growth hormone deficiency or Turner syndrome. Endocr J 2013;60: 57–64. [Medline]

18. Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in boys. Arch Dis Child 1970;45: 13–23. [Medline] [CrossRef]

19. Marshall WA, Tanner JM. Variations in pattern
20. Darendeliler F, Karagiannis G, Wilton P, Ranke MB, Albertsson-Wikland K, Anthony Price D, On Behalf Of The Kigs International Board. Recurrence of brain tumours in patients treated with growth hormone: analysis of KIGS (Pfizer International Growth Database). Acta Paediatr 2006;95: 1284–90. [Medline] [CrossRef]

21. Bakalov VK, Cooley MM, Quon MJ, Luo ML, Yanovski JA, Nelson LM, et al. Impaired insulin secretion in the Turner metabolic syndrome. J Clin Endocrinol Metab 2004;89: 3516–20. [Medline] [CrossRef]

22. Veening MA, Van Weissenbruch MM, Delemarre-Van De Waal HA. Glucose tolerance, insulin sensitivity, and insulin secretion in children born small for gestational age. J Clin Endocrinol Metab 2002;87: 4657–61. [Medline] [CrossRef]

23. Meacham LR, Sklar CA, Li S, Liu Q, Gimpel N, Yasui Y, et al. Diabetes mellitus in long-term survivors of childhood cancer. Increased risk associated with radiation therapy: a report for the childhood cancer survivor study. Arch Intern Med 2009;169: 1381–8. [Medline] [CrossRef]

24. Konovalov AN, Pitskhelauri DI. Principles of treatment of the pineal region tumors. Surg Neurol 2003;59: 250–68. [Medline] [CrossRef]

25. Woodmansee WW, Zimmermann AG, Child CJ, Rong Q, Erfurth EM, Beck-Peccoz P, et al. GeNeSIS and HypoCCS International Advisory Boards. Incidence of second neoplasm in childhood cancer survivors treated with GH: an analysis of GeNeSIS and HypoCCS. Eur J Endocrinol 2013;168: 565–73. [Medline] [CrossRef]

26. Wilton P, Mattsson AF, Darendeliler F. Growth hormone treatment in children is not associated with an increase in the incidence of cancer: experience from KIGS (Pfizer International Growth Database). J Pediatr 2010;157: 265–70. [Medline] [CrossRef]

27. Fradkin JE, Mills JL, Schonberger LB, Wysowski DK, Thomson R, Durako SJ, et al. Risk of leukemia after treatment with pituitary growth hormone. JAMA 1993;270: 2829–32. [Medline] [CrossRef]
37. Liubinas SV, Munshey AS, Kaye AH. Management of recurrent craniopharyngioma. J Clin Neurosci 2011;18: 451–7. [Medline] [CrossRef]

38. Shen L, Sun CM, Li XT, Liu CJ, Zhou YX. Growth hormone therapy and risk of recurrence/progression in intracranial tumors: a meta-analysis. Neurol Sci 2015;36: 1859–67. [Medline] [CrossRef]

39. Gupta DK, Ojha BK, Sarkar C, Mahapatra AK, Sharma BS, Mehta VS. Recurrence in pediatric craniopharyngiomas: analysis of clinical and histological features. Childs Nerv Syst 2006;22: 50–5. [Medline] [CrossRef]